Report cover image

Global Tumor Necrosis Factor Inhibitor Drugs Market Size Study by Product (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars), by Application (Rheumatoid Arthritis, Psoriasis, Ulcerative Colitis, Crohn’s Disease, and Others), by Sales Ch

Publisher Bizwit Research & Consulting
Published Jan 13, 2025
Length 285 Pages
SKU # BIZW19503000

Description

Global Tumor Necrosis Factor Inhibitor Drugs Market Size Study by Product (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars), by Application (Rheumatoid Arthritis, Psoriasis, Ulcerative Colitis, Crohn’s Disease, and Others), by Sales Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy), and Regional Forecasts 2022-2032


TNF inhibitors are pivotal in treating autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, and Crohn’s disease, by targeting and inhibiting the action of tumor necrosis factor, a cytokine that drives inflammation.

The increasing prevalence of autoimmune diseases globally is a key growth driver. Advancements in drug formulations, such as biosimilars, are creating opportunities for wider patient access and fostering competition in the market. Additionally, aging populations and heightened awareness of autoimmune conditions are propelling demand for effective treatment options.

Humira leads the product segment, accounting for 40.5% of the market share in 2024, owing to its versatility and established efficacy in managing multiple autoimmune diseases. Biosimilars are poised to emerge as a high-growth segment, with a projected CAGR of 15.5% during the forecast period, driven by affordability, increasing approvals, and expiration of patents for biologics like Humira.

Regional dynamics reveal North America as the dominant market, capturing 37.3% of the revenue share in 2024, due to its advanced healthcare infrastructure, significant patient pool, and robust pharmaceutical innovation. In the Asia Pacific region, the market is anticipated to grow at a CAGR of 4.5%, fueled by improvements in healthcare accessibility and heightened awareness of autoimmune therapies.

Major market players included in this report are:
• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• UCB S.A.
• Pfizer Inc.
• Novartis International AG
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi

The detailed segments and sub-segment of the market are explained below:

By Product:
• Humira
• Enbrel
• Remicade
• Simponi/Simponi Aria
• Cimzia
• Biosimilars

By Application:
• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis
• Crohn’s Disease
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Others

By Sales Channel:
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

By Region:
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
• Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
• Latin America
Brazil
Argentina
• Middle East & Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approaches.
• Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Tumor Necrosis Factor Inhibitor Drugs Market Executive Summary
1.1. Global Tumor Necrosis Factor Inhibitor Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Application
1.3.3. By Sales Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Tumor Necrosis Factor Inhibitor Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Tumor Necrosis Factor Inhibitor Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Autoimmune Diseases
3.1.2. Advancements in Biosimilar Development
3.1.3. Increasing Patient Awareness and Diagnostics
3.2. Market Challenges
3.2.1. High Cost of Biologics and Biosimilars
3.2.2. Stringent Regulatory Approvals
3.3. Market Opportunities
3.3.1. Expansion of Applications for TNF Inhibitors
3.3.2. Increasing Adoption of Biosimilars in Emerging Markets
Chapter 4. Global Tumor Necrosis Factor Inhibitor Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Industry Expert Perspective
4.6. Analyst Recommendation & Conclusion
Chapter 5. Global Tumor Necrosis Factor Inhibitor Drugs Market Size & Forecasts by Product (2022-2032)
5.1. Segment Dashboard
5.2. Humira
5.3. Enbrel
5.4. Remicade
5.5. Simponi/Simponi Aria
5.6. Cimzia
5.7. Biosimilars
Chapter 6. Global Tumor Necrosis Factor Inhibitor Drugs Market Size & Forecasts by Application (2022-2032)
6.1. Segment Dashboard
6.2. Rheumatoid Arthritis
6.3. Psoriasis
6.4. Psoriatic Arthritis
6.5. Ulcerative Colitis
6.6. Crohn’s Disease
6.7. Ankylosing Spondylitis
6.8. Juvenile Idiopathic Arthritis
6.9. Hidradenitis Suppurativa
6.10. Others
Chapter 7. Global Tumor Necrosis Factor Inhibitor Drugs Market Size & Forecasts by Sales Channel (2022-2032)
7.1. Segment Dashboard
7.2. Hospital Pharmacy
7.3. Specialty Pharmacy
7.4. Online Pharmacy
Chapter 8. Global Tumor Necrosis Factor Inhibitor Drugs Market Size & Forecasts by Region (2022-2032)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. UK
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Denmark
8.2.7. Sweden
8.2.8. Norway
8.3. Asia-Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Thailand
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.5. Middle East & Africa
8.5.1. South Africa
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Kuwait
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. AbbVie Inc.
9.1.2. Johnson & Johnson Services Inc.
9.1.3. Amgen Inc.
9.2. Top Market Strategies
9.3. Company Profiles
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
List of Tables
TABLE 1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Report Scope
TABLE 2. Global Tumor Necrosis Factor Inhibitor Drugs Market Estimates & Forecasts by Region, 2022-2032 (USD Billion)
TABLE 3. Global Tumor Necrosis Factor Inhibitor Drugs Market Estimates & Forecasts by Product, 2022-2032 (USD Billion)
TABLE 4. Global Tumor Necrosis Factor Inhibitor Drugs Market Estimates & Forecasts by Application, 2022-2032 (USD Billion)
TABLE 5. Global Tumor Necrosis Factor Inhibitor Drugs Market Estimates & Forecasts by Sales Channel, 2022-2032 (USD Billion)
TABLE 6. North America Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032 (USD Billion)
TABLE 7. Europe Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032 (USD Billion)
TABLE 8. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032 (USD Billion)
TABLE 9. Latin America Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032 (USD Billion)
TABLE 10. Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032 (USD Billion)
This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.
List of Figures
FIGURE 1. Global Tumor Necrosis Factor Inhibitor Drugs Market Research Methodology
FIGURE 2. Global Tumor Necrosis Factor Inhibitor Drugs Market Estimation Techniques
FIGURE 3. Global Tumor Necrosis Factor Inhibitor Drugs Market Size Estimates & Forecast Methods
FIGURE 4. Global Tumor Necrosis Factor Inhibitor Drugs Market Trends, 2024
FIGURE 5. Global Tumor Necrosis Factor Inhibitor Drugs Market Growth Prospects, 2022-2032
FIGURE 6. Global Tumor Necrosis Factor Inhibitor Drugs Market Porter’s Five Force Model
FIGURE 7. Global Tumor Necrosis Factor Inhibitor Drugs Market PESTEL Analysis
FIGURE 8. Global Tumor Necrosis Factor Inhibitor Drugs Market Value Chain Analysis
FIGURE 9. Global Tumor Necrosis Factor Inhibitor Drugs Market by Product, 2022 & 2032 (USD Billion)
FIGURE 10. Regional Snapshot of Tumor Necrosis Factor Inhibitor Drugs Market, 2022-2032
This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us